CIBERER Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2013
NCT02931071
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Spain | CIBER Enfermedades raras

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 2)

Epidermolysis Bullosa (Phase 2)

Epidermolysis Bullosa Dystrophica (Phase 2)

Fanconi Anemia (Phase 2)

Fanconi Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4